Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumors × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 37 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Renal Cell 5 Skin Neoplasms 4 Prostatic Neoplasms 4 Carcinoma, Hepatocellular 4 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Glioblastoma 3 Advanced Cancer 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Breast Neoplasms 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Turcot syndrome 1

Interventions

Carboplatin 3 Docetaxel 2 Cisplatin 2 BMS-753493 2 zimberelimab 1 tislelizumab 1 spartalizumab 1 pembrolizumab 1 olaparib 1 liposomal doxorubicin 1 linifanib 1 lenvatinib 1 ixabepilone 1 durvalumab 1 avelumab 1 avdoralimab 1 adavosertib 1 Nivolumab 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 Maximum Tolerated Dose 1 Linoleic Acids, Conjugated 1 Lapatinib 1 Irinotecan 1 Ipilimumab 1 Injections 1 Ifosfamide 1 Gemcitabine 1 Fluorouracil 1 Doxorubicin 1 Dosage Forms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡